Chris Markoch

Chris Markoch

InvestorPlace Contributor

Chris Markoch is a freelance financial writer who brings over 25 years in sales and marketing to help find the story behind the stock. Chris starts by asking the question, “So what?” and then uses fundamental and (some) technical analysis to add depth to that insight.

Stepping back from the “what” allows Chris to bring perspective that helps investors make wise decisions based on their risk tolerance and investing timeline.

Markoch would describe his writing as being for investors more than traders. He looks at equities through a long-term lens and that is reflected in his writing.

In addition to his articles on InvestorPlace, you can also find Chris’ writing on MarketBeat.com where he has collaborated on the e-book “5 Investing Trends That Will Define the Market in 2022.” You can find Chris on LinkedIn and on Twitter.

Recent Articles

Workhorse Has a Compelling Story If You Tune Out the News

By Chris Markoch, InvestorPlace Contributor

If you’re worth buying and holding a position in WKHS stock, it has a story that may make it a worthwhile investment.

Novavax May Profit From Life in the Slow Lane

By Chris Markoch, InvestorPlace Contributor

Novavax is attempting to bring a Covid-19 vaccine to market in a new way. This makes NVAX stock a risk with potential rewards.

Now’s the Time for Caution When it Comes to Array Technologies

By Chris Markoch, InvestorPlace Contributor

There are many reasons to believe that Array Technologies stock will be a strong renewable energy investment. That may be-- but maybe not right now.

Nvidia May Need to Get Worse Before it Gets Better

By Chris Markoch, InvestorPlace Contributor

Nvidia stock has a premium valuation but several catalysts may keep buyers interested. But with uncertainty likely to bring the market down, caution is advised.

Don’t Blame the Pandemic For the Problems With Naked Brands

By Chris Markoch, InvestorPlace Contributor

Naked Brands is giving investors every reason to believe they will not be in business much longer, but traders are still giving NAKD stock a look.

Virgin Galactic Is No Laughing Matter

By Chris Markoch, InvestorPlace Contributor

Virgin Galactic shares got an artificial boost from a bullish call that turned out to be a joke. SPCE stock is still a speculative play.

Despite Legal Drama, Catalyst Pharmaceuticals Looks Oversold

By Chris Markoch, InvestorPlace Contributor

Catalyst Pharmaceuticals stock has been on a wild ride since its drug got FDA approval -- and despite legal drama, it may be worth the risk.

Your First Instinct About Sorrento Therapeutics Is Probably Right

By Chris Markoch, InvestorPlace Contributor

SRNE stock is down nearly 66% since August. The company is taking many swings at finding solutions for Covid-19, but it's runway simply isn't long enough.

Chesapeake Energy Must Be Praying for a Trump Victory

By Chris Markoch, InvestorPlace Contributor

Chesapeake Energy stock is worthless coming out of bankruptcy and the company's narrow path to relevance will be complicated by a Biden win.

It’s Time to Place Your Bets On Landcadia Holdings

By Chris Markoch, InvestorPlace Contributor

As virus cases surge, a range of outcomes are possible for the online gambling sector. That means now may not be the time to buy LCA stock.

Load More